ArticleBritish journal of haematology2010
The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research.
Article in British journal of haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Pooled it
- Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards.BMC cancer · 2026Article
- Trends and disparities in Non-Hodgkin Lymphoma related mortality in the United States, 1999-2020.PloS one · 2025Article
- The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.American journal of hematology · 2024Article
- Article
- Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.Blood advances · 2022Article
- Cohort Profile Update: The Haematological Malignancy Research Network (HMRN) UK population-based cohorts.International journal of epidemiology · 2022Article
- Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.Annals of medicine and surgery (2012) · 2022Article
- Article
- Article
- Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.Open medicine (Warsaw, Poland) · 2021Article
- Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication.Frontiers in immunology · 2021Article
- Observational
- Risk of mature B-cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network.International journal of cancer · 2020Article
- Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study.International journal of environmental research and public health · 2020Article
- Article
- Article
- Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.PloS one · 2020Article
- Article
- Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network.BJGP open · 2019Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Haematological Malignancy Research Network (HMRN) was established in 2004 to provide robust generalizable data to inform clinical practice and research. It comprises an ongoing population-based cohort of patients newly diagnosed by a single integrated haematopathology laboratory in two adjacent UK Cancer Networks (population 3.6 million). With an emphasis on primary-source data, prognostic factors, sequential treatment/response history, and socio-demographic details are recorded to clinical trial standards. Data on 8131 patients diagnosed over the 4 years 2004-08 are examined here using the latest World Health Organization classification. HMRN captures all diagnoses (adult and paediatric) and the diagnostic age ranged from 4 weeks to 99 years (median 70.4 years). In line with published estimates, first-line clinical trial entry varied widely by disease subtype and age, falling from 59.5% in those aged <15 years to 1.9% in those aged over 75 years - underscoring the need for contextual population-based treatment and response data of the type collected by HMRN. The critical importance of incorporating molecular and prognostic markers into comparative survival analyses is illustrated with reference to diffuse-large B-cell lymphoma, acute myeloid leukaemia and myeloma. With respect to aetiology, several descriptive factors are highlighted and discussed, including the unexplained male predominance evident for most subtypes across all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.